Memory function in a mouse genetic model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 25, Issue 3, 2011, Pages 433-444

  Avdesh, Avdesh ^a,c   Wong, Patrick ^b   Martins, Ralph N ^a,c,d,e   Martin Iverson, Mathew T ^b,c,d  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

8 arm radial maze; Alzheimer's disease; ApoE knock out mice; memory

Indexed keywords

APOLIPOPROTEIN E;

ALZHEIMER DISEASE; AMBIGUITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; GENE INACTIVATION; MALE; MAZE TEST; MEMORY; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SENILE PLAQUE;

EID: 79960814910     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101944     Document Type: Article

References (68)

1. Traykov L, Baudic S, Raoux N, Latour F, Rieu D, Smagghe A, Rigaud AS (2005) Patterns of memory impairment and perseverative behavior discriminate early Alzheimer's disease from subcortical vascular dementia. J Neurol Sci 229-230, 75-79. (Pubitemid 40341568)
2. Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) The spectrum of behavioral changes in Alzheimer's disease. Neurology 46, 130-135. (Pubitemid 26156117)
3. Ewbank DC (1999) Deaths attributableto Alzheimer's disease in the United States. Am J Public Health 89, 90-92. (Pubitemid 29281977)
4. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60, 1119-1122. (Pubitemid 36975801)
5. Ernst RL, Hay JW (1994) The US economic and social costsof Alzheimer's disease revisited. Am J Public Health 84, 1261-1264. (Pubitemid 24250694)
6. Qiu C, Xu W, Fratiglioni L (2010) Vascular and psychoso-cial factors in Alzheimer's disease: epidemiological evidence toward intervention. J Alzheimers Dis 20, 689-697.
7. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156, 445-453. (Pubitemid 34976983)
8. Chan A, Shea TB (2010) Apolipoprotein e3 as a risk factor for Alzheimer's disease under conditions of nutritional imbalance. J Alzheimers Dis 21, 49-55.
9. Perry G, Cash AD, Smith MA (2002) Alzheimer Disease and Oxidative Stress. J Biomed Biotechnol 2, 120-123. (Pubitemid 44204507)
10. Carr DB, Goate A, Phil D, Morris JC (1997) Current concepts in the pathogenesis of Alzheimer's disease. Am J Med 103, 3S-10S. (Pubitemid 27444159)
11. Weisgraber KH, Mahley RW (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 10, 1485-1494. (Pubitemid 26384445)
12. Kamboh MI (1995) Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease. Hum Biol 67, 195-215.
13. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45, 1092-1096.
14. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease andkuru plaque amyloidin Creutzfeldt-Jakob disease. Brain Res 541, 163-166.
15. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90, 9649-9653. (Pubitemid 23315843)
16. Ohm TG, Kirca M, Bohl J, Scharnagl H, Gross W, Marz W (1995) Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofib-rillary tangle formation. Neuroscience 66, 583-587.
17. Gordon I, Grauer E, Genis I, Sehayek E, Michaelson DM (1995) Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci Lett 199, 1-4.
18. Oitzl MS, Mulder M, Lucassen PJ, Havekes LM, Groo-tendorst J, de Kloet ER (1997) Severe learning deficits in apolipoprotein E-knockout mice in a water maze task. Brain Res 752, 189-196. (Pubitemid 27143913)
19. Krzywkowski P, Ghribi O, Gagne J, Chabot C, Kar S, Rochford J, Massicotte G, Poirier J (1999) Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice. Neuroscience 92, 1273-1286. (Pubitemid 29292564)
20. Genis I, Gordon I, Sehayek E, Michaelson DM (1995) Phosphorylation of tau in apolipoprotein E-deficient mice. Neurosci Lett 199, 5-8.
21. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343-353.
22. Martins RN, Harper CG, Stokes GB, Masters CL (1986) Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 46, 1042-1045. (Pubitemid 16010948)
23. Pratico D (2002) Alzheimer's disease and oxygen radicals: new insights. Biochem Pharmacol 63, 563-567. (Pubitemid 34457689)
24. Smith MA, Casadesus G, Joseph JA, Perry G (2002) Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 33, 1194-1199. (Pubitemid 35246587)
25. Gabbita SP, Lovell MA, Markesbery WR (1998) Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71, 2034-2040. (Pubitemid 28491559)
26. Butterfield DA, Castegna A, Lauderback CM, Drake J (2002) Evidence that amyloid beta-peptide-induced lipid peroxida-tion and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23, 655-664. (Pubitemid 35217687)
27. Durany N, Munch G, Michel T, Riederer P (1999) Investigations on oxidative stress and therapeutical implications in dementia. Eur Arch Psychiatry Clin Neurosci 249 (Suppl 3), 68-73.
28. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Beher D, Masters CL, Beyreuther K (1997) Reactive oxygen species and Alzheimer's disease. Biochem Pharmacol 54, 533-539. (Pubitemid 27405186)
29. Miyata M, Smith JD (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14, 55-61. (Pubitemid 26301547)
30. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, et al. (1995) Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1, 693-699.
31. Goedert M, Spillantini MG (2006) A century of Alzheimer's disease. Science 314, 777-781. (Pubitemid 44706636)
32. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70, 2212-2215. (Pubitemid 28207848)
33. Behl C (1999) Alzheimer'sdisease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol 57, 301-323. (Pubitemid 28559237)
34. Kheirandish L, Row BW, Li RC, Brittian KR, Gozal D (2005) Apolipoprotein E-deficient mice exhibit increased vulnerability to intermittent hypoxia-induced spatial learning deficits. Sleep 28, 1412-1417. (Pubitemid 41572792)
35. Lomnitski L, Chapman S, Hochman A, Kohen R, Shohami E, Chen Y, Trembovler V, Michaelson DM (1999) Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury. Biochim Biophys Acta 1453, 359-368. (Pubitemid 29146160)
36. Pratico D, Tangirala RK, Rader DJ, Rokach J, Fitz Gerald GA (1998) Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in Apo E-deficient mice. Nat Med 4, 1189-1192. (Pubitemid 28468835)
37. Anderson R, Barnes JC, Bliss TV, Cain DP, Cambon K, Davies HA, Errington ML, Fellows LA, Gray RA, Hoh T, Stewart M, Large CH, Higgins GA (1998) Behavioural, physiological and morphological analysis ofa line of apolipoprotein E knockout mouse. Neuroscience 85, 93-110. (Pubitemid 28228418)
38. Anderson R, Higgins GA (1997) Absence of central cholin-ergic deficits in Apo E knockout mice. Psychopharmacology (Berl) 132, 135-144. (Pubitemid 27338988)
39. Puolivali J, Miettinen R, Pradier L, Riekkinen P, Jr (2000) Apolipoprotein E-deficient mice are not more susceptible to the biochemical and memory deficits induced by nucleus basalis lesion. Neuroscience 96, 291-297. (Pubitemid 30100410)
40. Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, Cracciolo JR, Rojiani A, Wu X, Bales KR, Paul SM, Potter H (2004) Cognitive impairment in PDAPP mice depends on Apo E and ACT-catalyzed amyloid formation. Neurobiol Aging 25, 1153-1167. (Pubitemid 39094018)
41. Morris RG, Anderson E, Lynch GS, Baudry M (1986) Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319, 774-776. (Pubitemid 16145031)
42. Holscher C (1999) Stress impairs performanceinspatial water maze learning tasks. Behav Brain Res 100, 225-235. (Pubitemid 29130257)
43. Kaneto H (1997) Learning/memory processes under stress conditions. Behav Brain Res 83, 71-74. (Pubitemid 27086617)
44. Grootendorst J, de Kloet ER, Dalm S, Oitzl MS (2001) Rever-salofcognitive deficitofapolipoprotein Eknockout mice after repeated exposure to a common environmental experience. Neuroscience 108, 237-247. (Pubitemid 33152965)
45. Cain DP, Saucier D, Hall J, Hargreaves EL, Boon F (1996) Detailed behavioral analysis of water maze acquisition under APV or CNQX: contribution of sensorimotor disturbances to drug-induced acquisition deficits. Behav Neurosci 110, 86-102. (Pubitemid 26068798)
46. Olton DS, Markovska AL (1993) Mazes: their use in delayed conditional discriminations and place discriminations. In Methods in Behavioral Pharmacology, Von Haaren F, ed., Elsevier, Amsterdam, pp. 195-216.
47. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD (1995) Neurodegeneration in the central nervous system of apo E-deficient mice. Exp Neurol 136, 107-122.
48. Grootendorst J, Bour A, Vogel E, Kelche C, Sullivan PM, Dodart JC, Bales K, Mathis C (2005) Human apo E targeted replacement mouse lines: h-apo E4 and h-apo E3 mice differ on spatial memory performance and avoidance behavior. Behav Brain Res 159, 1-14. (Pubitemid 40410579)
49. Selley ML, Close DR, Stern SE (2002) The effectof increased concentrations of homocysteine on the concentration of (E) -4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 23, 383-388. (Pubitemid 34312021)
50. Veurink G, Liu D, Taddei K, Perry G, Smith MA, Robertson TA, Hone E, Groth DM, Atwood CS, Martins RN (2003) Reduction of inclusion body pathology in Apo E-deficient mice fed a combination of antioxidants. Free Radic Biol Med 34, 1070-1077. (Pubitemid 36398567)
51. Chen H, Tappel AL (1995) Protection of vitamin E, selenium, trolox C, ascorbic acid palmitate, acetylcysteine, coenzyme Q0, coenzyme Q10, beta-carotene, canthaxanthin, and (+) -catechin against oxidative damage to rat blood and tissues in vivo. Free Radic Biol Med 18, 949-953.
52. Crawford RS, Kirk EA, Rosenfeld ME, Le Boeuf RC, Chait A (1998) Dietary antioxidants inhibit development of fatty streak lesions in the LDL receptor-deficient mouse. Arte-rioscler Thromb Vasc Biol 18, 1506-1513. (Pubitemid 28421890)
53. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR (2000) Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54, 1265-1272. (Pubitemid 30174045)
54. Cornelli U (2010) Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants. Neu-rodegener Dis 7, 193-202.
55. Grundman M (2000) Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 71, 630S-636S. (Pubitemid 30061248)
56. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegi-line, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336, 1216-1222. (Pubitemid 27183651)
57. Paleologos M, Cumming RG, Lazarus R (1998) Cohort study of vitamin Cintake and cognitive impairment.Am JEpidemiol 148, 45-50. (Pubitemid 28317544)
58. Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R (1996) Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29, 47-56. (Pubitemid 26116561)
59. Kiess HO (1989) Statistical Concepts for the Behavioural Sciences, Allyn and Bacon Boston, 673.
60. Robertson TA, Dutton NS, Martins RN, Roses AD, Kakulas BA, Papadimitriou JM (1997) Beta-amyloid protein- containing inclusions in skeletal muscle of apolipoprotein-E-deficient mice. Am J Pathol 150, 417-427. (Pubitemid 27073771)
61. Robertson TA, Dutton NS, Martins RN, Roses AD, Kaku-las BA, Papadimitriou JM (1998) Age-related congophilic inclusions in the brains of apolipoprotein E-deficient mice. Neuroscience 82, 171-180.
62. Fisher A, Brandeis R, Chapman S, Pittel Z, Michaelson DM (1998) M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J Neurochem 70, 1991-1997. (Pubitemid 28207822)
63. Chapman S, Michaelson DM (1998) Specific neurochemical derangements of brain projecting neurons in apolipoprotein E-deficient mice. J Neurochem 70, 708-714. (Pubitemid 28079360)
64. Irizarry MC, Rebeck GW, Cheung B, Bales K, Paul SM, Holz-man D, Hyman BT (2000) Modulation of A beta deposition in APP transgenic mice byan apolipoprotein Enull background. Ann N Y Acad Sci 920, 171-178. (Pubitemid 32056566)
65. Irizarry MC, Cheung BS, Rebeck GW, Paul SM, Bales KR, Hyman BT (2000) Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP (V717F) transgenic mice. Acta Neuropathol 100, 451-458.
66. Verdile G, Fuller S, Atwood CS, Laws SM, Gandy SE, Martins RN (2004) The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol Res 50, 397-409. (Pubitemid 39078531)
67. Miyakawa T, Yagi T, Kagiyama A, Niki H (1996) Radial maze performance, open-field and elevated plus-maze behaviors in Fyn-kinase deficient mice: further evidence for increased fearfulness. Brain Res Mol Brain Res 37, 145-150. (Pubitemid 26147984)
68. Lubinsky T, Rich JB, Anderson ND (2009) Errorless learning and elaborative self-generation in healthy older adults and individuals with amnestic mild cognitive impairment: mnemonic benefits and mechanisms. J Int Neuropsychol Soc 15, 704-716.